Ross Lisa L, Horton Joseph, Hasan Samiul, Brown James R, Murphy Daniel, DeJesus Edwin, Potter Martin, LaMarca Anthony, Melendez-Rivera Ivan, Ward Douglas, Uy Jonathon, Shaefer Mark S
ViiV HealthCare, Research Triangle Park, North Carolina, United States of America.
GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America.
PLoS One. 2014 Feb 26;9(2):e89611. doi: 10.1371/journal.pone.0089611. eCollection 2014.
Factors that contribute to the transmission of human immunodeficiency virus type 1 (HIV-1), especially drug-resistant HIV-1 variants remain a significant public health concern. In-depth phylogenetic analyses of viral sequences obtained in the screening phase from antiretroviral-naïve HIV-infected patients seeking enrollment in EPZ108859, a large open-label study in the USA, Canada and Puerto Rico (ClinicalTrials.gov NCT00440947) were examined for insights into the roles of drug resistance and epidemiological factors that could impact disease dissemination. Viral transmission clusters (VTCs) were initially predicted from a phylogenetic analysis of population level HIV-1 pol sequences obtained from 690 antiretroviral-naïve subjects in 2007. Subsequently, the predicted VTCs were tested for robustness by ultra deep sequencing (UDS) using pyrosequencing technology and further phylogenetic analyses. The demographic characteristics of clustered and non-clustered subjects were then compared. From 690 subjects, 69 were assigned to 1 of 30 VTCs, each containing 2 to 5 subjects. Race composition of VTCs were significantly more likely to be white (72% vs. 60%; p = 0.04). VTCs had fewer reverse transcriptase and major PI resistance mutations (9% vs. 24%; p = 0.002) than non-clustered sequences. Both men-who-have-sex-with-men (MSM) (68% vs. 48%; p = 0.001) and Canadians (29% vs. 14%; p = 0.03) were significantly more frequent in VTCs than non-clustered sequences. Of the 515 subjects who initiated antiretroviral therapy, 33 experienced confirmed virologic failure through 144 weeks while only 3/33 were from VTCs. Fewer VTCs subjects (as compared to those with non-clustering virus) had HIV-1 with resistance-associated mutations or experienced virologic failure during the course of the study. Our analysis shows specific geographical and drug resistance trends that correlate well with transmission clusters defined by HIV sequences of similarity. Furthermore, our study demonstrates the utility of molecular and epidemiological analysis of VTCs for identifying population-specific risks associated with HIV-1 transmission and developing effective local healthcare strategies.
导致1型人类免疫缺陷病毒(HIV-1)传播的因素,尤其是耐药性HIV-1变体,仍然是一个重大的公共卫生问题。对在美国、加拿大和波多黎各进行的一项大型开放标签研究(ClinicalTrials.gov NCT00440947)中,在筛查阶段从初治HIV感染患者中获得的病毒序列进行深入系统发育分析,以深入了解可能影响疾病传播的耐药性和流行病学因素的作用。病毒传播簇(VTC)最初是通过对2007年从690名初治抗逆转录病毒治疗的受试者中获得的群体水平HIV-1 pol序列进行系统发育分析预测的。随后,使用焦磷酸测序技术通过超深度测序(UDS)和进一步的系统发育分析对预测的VTC进行稳健性测试。然后比较聚类和非聚类受试者的人口统计学特征。在690名受试者中,69人被分配到30个VTC中的1个,每个VTC包含2至5名受试者。VTC的种族构成更可能是白人(72%对60%;p=0.04)。与非聚类序列相比,VTC的逆转录酶和主要蛋白酶抑制剂耐药性突变较少(9%对24%;p=0.002)。男男性行为者(MSM)(68%对48%;p=0.001)和加拿大人(29%对14%;p=0.03)在VTC中比在非聚类序列中明显更常见。在开始抗逆转录病毒治疗的515名受试者中,33人在144周内经历了确诊的病毒学失败,而只有3/33来自VTC。在研究过程中,VTC受试者(与非聚类病毒受试者相比)携带与耐药相关突变的HIV-1或经历病毒学失败的情况较少。我们的分析显示了与相似性HIV序列定义的传播簇密切相关的特定地理和耐药趋势。此外,我们的研究证明了对VTC进行分子和流行病学分析在识别与HIV-1传播相关的人群特异性风险以及制定有效的当地医疗保健策略方面的实用性。